You just read:

Immune Pharmaceuticals Announces the launch of REMAIN ™ , an international Overall Survival study with Ceplene® and low dose Proleukin® in REmission MAINtenance in Acute Myeloid Leukemia

News provided by

Immune Pharmaceuticals Inc.

Feb 17, 2017, 09:15 ET